Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
License revenue	$ 170,000	$ 0	$ 170,000	$ 19,880,000
Operating expenses:
Research and development	17,949,000	16,026,000	33,409,000	21,611,000
Acquisition of in-process research and development	357,000	7,962,000	357,000	8,934,000
General and administrative	17,221,000	37,331,000	35,203,000	46,604,000
Total operating expenses	35,527,000	61,319,000	68,969,000	77,149,000
Loss from operations	(35,357,000)	(61,319,000)	(68,799,000)	(57,269,000)
Other income (expense), net:
Interest income	117,000	35,000	215,000	72,000
Change in fair value of contingent consideration liability - related parties	95,000	(911,000)	95,000	(660,000)
Change in fair value of derivative liability	0	0	0	41,000
Change in fair value of warrant liability	53,000	0	53,000	0
Change in fair value of securities carried at fair value	(584,000)	0	(1,324,000)	0
Unrealized loss on other investments held at fair value	0	(5,460,000)	0	(5,460,000)
Loss on conversion of convertible promissory notes	0	(513,000)	0	(513,000)
Gain on consolidation of a variable interest entity	0	3,543,000	0	3,543,000
Foreign exchange gain (loss), net	4,882,000	(2,558,000)	7,045,000	(1,068,000)
Other expense, net	(12,000)	(118,000)	(12,000)	(234,000)
Total other income (expense), net	4,551,000	(5,982,000)	6,072,000	(4,279,000)
Loss before income taxes	(30,806,000)	(67,301,000)	(62,727,000)	(61,548,000)
Provision for income taxes	(51,000)	(58,000)	(92,000)	(64,000)
Gain on dilution of equity method investment	(0)	16,923,000	(0)	16,923,000
Losses from investments in equity method investees, net of tax	(6,652,000)	(2,937,000)	(12,248,000)	(4,640,000)
Net loss	(37,509,000)	(53,373,000)	(75,067,000)	(49,329,000)
Net loss attributable to redeemable noncontrolling interests and noncontrolling interests	(891,000)	(4,912,000)	(1,580,000)	(1,556,000)
Net loss attributable to ATAI Life Sciences N.V. stockholders	$ (36,618,000)	$ (48,461,000)	$ (73,487,000)	$ (47,773,000)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - basic	$ (0.24)	$ (0.37)	$ (0.48)	$ (0.38)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - diluted	$ (0.24)	$ (0.37)	$ (0.48)	$ (0.38)
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - basic	153,971,202	132,265,075	153,751,456	125,797,732
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders - diluted	153,971,202	132,265,075	153,751,456	125,797,732